Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Dapagliflozin and Right Heart Recovery After ASD Device Closure

NCT: NCT07823972 · NOT_YET_RECRUITING

NCT IDNCT07823972
StatusNOT_YET_RECRUITING
Start Date2026-11-01
Completion2029-01-30
SponsorAssiut University (OTHER)
First posted
Last updated

Brief Summary

The aim of this study is to evaluate the clinical and echocardiographic influence of dapagliflozin on right ventricular reverse remodeling in adult patients following successful transcatheter Atrial Septal Defect (ASD) device closure.

Frequently Asked Questions

What is Dapagliflozin and Right Heart Recovery After ASD Device Closure?

Dapagliflozin and Right Heart Recovery After ASD Device Closure is a clinical trial registered under NCT07823972. Current status: NOT_YET_RECRUITING.

What is the status of NCT07823972?

The current status of NCT07823972 (Dapagliflozin and Right Heart Recovery After ASD Device Closure) is: NOT_YET_RECRUITING.

When did Dapagliflozin and Right Heart Recovery After ASD Device Closure start?

Dapagliflozin and Right Heart Recovery After ASD Device Closure started on 2026-11-01.

Related Devices

PMA P200032Transcatheter septal occluder (atrial)Occlutech Holding AG

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑